Study of JS212 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of advanced cancer that has been confirmed by a biopsy or other lab test.
- You are able to take care of yourself (up and about, not bedridden).
- Your cancer has at least one tumor that can be measured on a scan.
- You have not had certain lung conditions, uncontrolled high blood pressure, or active cancer in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
Hear when a new Advanced Malignant Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.